US › Healthcare

Cardiff Oncology Inc (CRDF)

US · Healthcare · Biotechnology

$0.93-0.55%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$41,000
Revenue YoY
-62.4%
Net profit
$-12.3M
Profit YoY
+8.1%
EPS
$-0.18
EPS estimate
$-0.12
Net margin
-30,109.8%

EPS came in at -0.18 against a street estimate of -0.12 — a miss of 50.0%.

Key statistics

Market cap
$66.5M
Forward P/E
0.0
P/B
1.93
Book value
$0.51
EPS (TTM)
$-0.67
52-week high
$3.31
52-week low
$0.76
50-day MA
$1.29
200-day MA
$1.88
Beta
1.44

Analyst view

Analysts rate Cardiff Oncology Inc a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $5.21.

Shareholding

Insiders
6.12%
Institutions
28.77%

Largest institutional holders

FundStake
BlackRock Inc5.12%
Vanguard Capital Management, LLC3.67%
LAURION CAPITAL MANAGEMENT LP3.40%
Pfizer Inc3.10%
Geode Capital Management, LLC2.06%
Franklin Resources Inc1.55%
State Street Corp1.53%
Blair William & Co1.19%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Cardiff Oncology Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.